GEN Exclusives

More »

GEN News Highlights

More »
Oct 11, 2007

Maas Biolab Awarded $2.1M to Enable Studies on Intrathecal Delivery of ALS Drug

  • Maas Biolab received an SBIR grant of $2.1 million to advance research on its drug candidate for amyotrophic lateral sclerosis (ALS). The National Institute of Neurological Disorders and Stroke grant extends over three years.

    The compound, known as Mitogard®, is a formulation of the direct mitochondrial neuroprotectant cyclosporine. It is the only cyclosporine compound designed for cerebrospinal fluid administration, according to Maas Biolab.

    The company believes that intrathecal delivery of Mitogard will overcome challenges faced by systemic cyclosporine, which does not easily reach the brain and spinal cord. Dose-escalation toxicology and pharmacokinetics safety studies will be performed by Northern Biomedical Research to enable IND approval for ALS clinical trials.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »